Completed PHASE1 INTERVENTIONAL 4-arm NCT03657264

Cardiac Safety Evaluation of P03277

Thorough QT/QTc Study to Assess the Electrocardiographic Safety of a New Gadolinium-based Contrast Agent P03277 in Healthy Volunteers

Sponsor: Guerbet

Conditions Healthy Volunteers

Interventions Moxifloxacin 400mg NaCl 0.9% P03277 0.1 mmol/kg P03277 0.3 mmol/kg

Updated 8 times since 2018 Last updated: Mar 22, 2022 Started: Aug 21, 2017 Primary completion: Jun 7, 2018 Completion: Jun 7, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy Volunteers and is currently completed. Guerbet leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Sep 2022 — Jul 2024 [monthly]

Completed PHASE1
Jun 2021 — Sep 2022 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jan 2021 — Jun 2021 [monthly]

Completed PHASE1
Sep 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Oct 2018 — Sep 2019 [monthly]

Active Not Recruiting PHASE1

First recorded

Aug 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guerbet

Data source: Guerbet

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Antwerp, Belgium